Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive RT in HPV-related High Risk Oropharynx Cancer
NCT06234748Phase 2Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2023
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in oropharyngeal cancer, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Toxicity of treatment based off of Adverse Events collected per CTCAE v5.0 at 3 years. Started Dec 2023; status: active, not recruiting.
02
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NCT06234748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234748.